The Relative Expression of ERα Isoforms ERα66 and ERα36 Controls the Cellular Response to 24R,25-Dihydroxyvitamin D3 in Breast Cancer.

ABSTRACT: Vitamin D3 and its metabolites have antitumorigenic properties in vitro and in vivo; however, clinical trials and retrospective studies on the effectiveness of vitamin D3 oral supplementation against cancer have been inconclusive. One reason for this may be that clinical trials ignore the complex vitamin D metabolome and the many active vitamin D3 metabolites present in the body. Recent work by our lab showed that 24R,25(OH)₂D₃, a vitamin D₃ metabolite that is active in chondrocyte proliferation and differentiation, has antitumorigenic properties in estrogen receptor alpha-66 (ERα66)-positive (ER⁺) breast cancer, but not in ERα66-negative (ER^-) breast cancer. Here we show that 24R,25(OH)₂D₃ is protum

SUBMITTER: Verma A 

PROVIDER: S-EPMC9250782 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature